高级检索
当前位置: 首页 > 详情页

Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Southwest Med Univ, Sch Pharm, Dept Pharmacol, Lab Mol Pharmacol, Luzhou, Peoples R China [2]Sichuan Coll Tradit Chinese Med, Res & Expt Ctr, Mianyang, Peoples R China [3]Cell Therapy & Cell Drugs Luzhou Key Lab, Luzhou, Peoples R China [4]South Sichuan Inst Translat Med, Luzhou, Peoples R China [5]Southern Med Univ, Shenzhen Hosp, Dept Gastroenterol, Shenzhen, Guangdong, Peoples R China [6]Gulin Tradit Chinese Med Hosp, Luzhou, Peoples R China
出处:
ISSN:

关键词: gut microbiota hepatocellular carcinoma (HCC) tumor microenvironment (TME) antibiotics probiotics prebiotics fecal microbiota transplantation (FMT) immunotherapy

摘要:
The gut microbiota, a complex microbial ecosystem closely connected to the liver via the portal vein, has emerged as a critical regulator of liver health and disease. Numerous studies have underscored its role in the onset and progression of liver disorders, including alcoholic liver disease, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). This review provides a comprehensive overview of current insights into the influence of the gut microbiota on HCC progression, particularly its effects on immune cells within the HCC tumor microenvironment (TME). Furthermore, we explore the potential of gut microbiota-targeted interventions, such as antibiotics, probiotics, prebiotics, and fecal microbiota transplantation (FMT), to modulate the immune response and improve outcomes of immunotherapy in HCC. By synthesizing insights from recent studies, this review aims to highlight microbiota-based strategies that may enhance immunotherapy outcomes, advancing personalized approaches in HCC treatment.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 2 区 医学
小类 | 2 区 免疫学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 免疫学
JCR分区:
出版当年[2025]版:
最新[2023]版:
Q1 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2024版]

第一作者:
第一作者机构: [1]Southwest Med Univ, Sch Pharm, Dept Pharmacol, Lab Mol Pharmacol, Luzhou, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Southwest Med Univ, Sch Pharm, Dept Pharmacol, Lab Mol Pharmacol, Luzhou, Peoples R China [2]Sichuan Coll Tradit Chinese Med, Res & Expt Ctr, Mianyang, Peoples R China [3]Cell Therapy & Cell Drugs Luzhou Key Lab, Luzhou, Peoples R China [4]South Sichuan Inst Translat Med, Luzhou, Peoples R China [6]Gulin Tradit Chinese Med Hosp, Luzhou, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:57668 今日访问量:1 总访问量:4767 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号